Business
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial is
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of the bone marrow in patients with p53-mutated breast cancer being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D)AC+D is a highly toxic chemotherapy regimen, causing severe neutropenia in up to 75% of patients and alopecia in approximately 90% of patientsInitial interim results anticipated in 4Q2022Aileron to host a virtual KOL investor event today at 4:00 pm ET BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced it has treated the first patients in its Phase 1b randomized, controlled clinical trial evaluating ALRN-6924 to protect against chemotherapy-induced neutropenia and other bone marrow toxicities, as well as toxicities outside of the bone marrow in patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D). Nearly 1 million patients each year are diagnosed with a p53-mutated cancer in the US. Aileron is pioneering a precision medicine-based approach that is designed to enable the selective chemoprotection of healthy, normal cells in patients with p53-mutated cancers who are receiving chemotherapy without protecting their cancer cells from chemotherapy. “Dosing of the first patients in our Phase 1b trial in patients with p53-mutated neoadjuvant breast cancer is an important step in advancing our vision to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron Therapeutics. “The severe toxicity profile of AC+D will enable us to evaluate ALRN-6924’s protective effect against multiple chemotherapy-induced toxicities. Moreover, this breast cancer trial may potentially open an additional regulatory opportunity with established precedents for supportive care drug approvals.” AC+D, a standard of care for patients with neoadjuvant breast cancer, is a hi...